Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673176 · ClinicalTrials.gov registry record · NA
Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT03673176: Completed NA study, sponsored by Stanford University.
NCT03673176 is a NA study that has completed, run by Stanford University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03673176, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Since medical therapies offer only modest palliation and minimal hopes for improved survival to COPD patients, surgical therapies have been designed that may provide greater benefits in selected patients. Lung transplantation, for example, clearly improves survival and quality of life in patients with end stage COPD. This comes at substantial economic cost, however, as well as the at the cost of complications that may result from the complex surgery and from life-long immunosuppression. In addition, nearly all lung transplants will fail within 5 years as a result of progressive bronchiolitis obliterans, which we currently have no way to prevent or treat. A second operation designed to treat severe COPD patients is lung volume reduction surgery (LVRS). This operation, designed for patients with predominant emphysema rather than chronic bronchitis, is among the most carefully studied operations ever developed. We believe that by reducing the volume of emphysematous lung with the precise target localization made possible by image-guided SABR, that we will be able to duplicate the benefits of surgical lung volume reduction with far less risk. We believe that this may represent a major advance in the therapy of emphysema - a highly prevalent disease. It may provide not only palliation but also increased survival, as does surgical lung volume reduction, in carefully selected patients.
Interventions
- RADIATION Stereotactic Ablative Radiotherapy (SABR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-02-11 |
| Est. Completion | 2021-08-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03673176
The ClinicalTrials.gov registry entry for NCT03673176 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Ablative Radiotherapy (SABR) is the first listed.
NCT03673176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03673176 about?
NCT03673176 is a clinical study titled "Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy". Since medical therapies offer only modest palliation and minimal hopes for improved survival to COPD patients, surgical therapies have been designed that may provide greater benefits in selected patients. Lung transplantation, for example, clearly improves survival and quality of life in patients wi...
What is the current status of trial NCT03673176?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2013-02-11. Estimated completion is 2021-08-02.
What interventions are being tested in trial NCT03673176?
The interventions under investigation include: Stereotactic Ablative Radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT03673176?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.